Genprex
Genprex is a United States-based biotechnology company running 2 late-stage cancer trials of quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer.
Overview
Genprex, based in Austin, the United States, is a biotechnology company. Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes by reintroducing tumour suppressor genes. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer. The largest, NCT04486833 (Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib), plans to enrol 158 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyEpicentRx
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.